Mounjaro and Trulicity are two injectable medications that treat type 2 diabetes. Learn more about their key similarities, ...

or molecular structure of GLP-1 agonist agent (semaglutide [Ozempic], liraglutide [Victoza], dulaglutide [Trulicity], or exenatide [Byetta, Bydureon]). There was, however, an inverse association ...

There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

By screening people for eating disorders and disordered eating before these medications are prescribed, we can prevent ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 ...

For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced ...

A recent study suggests that GLP-1 receptor agonists (GLP-1RAs) may lower the risk of hematologic cancers, including leukemia ...

Results presented here showed patients who had significant weight loss prior to total hip arthroplasty with use of a GLP-1 ...

Right now, about 12% of American aged 18 or older (or 1 in 8 adults) are taking GLP-1 — glucagon-like peptide-1 — receptor agonists ... Mounjaro, Trulicity and other similar drugs work ...